A 48-year-old woman with a 15-year history of intravenous drug use presents with progressive fatigue, right upper quadrant pain, and ascites. On examination: spider angiomas, palmar erythema, ascites, hepatosplenomegaly. Laboratory findings: AST 89 IU/L, ALT 62 IU/L, ALP 156 IU/L, bilirubin 2.8 mg/dL, albumin 2.9 g/dL, INR 1.8, platelet count 68,000/μL. Serological tests: anti-HCV antibody positive, HCV RNA positive (viral load 2.4 million IU/mL), anti-HAV IgG positive, anti-HBc positive, HBsAg negative. Ultrasound abdomen: cirrhotic liver echotexture, portal vein diameter 13 mm, ascites. What is the most appropriate next step in management?

Explanation

## Diagnosis and Clinical Context **Key Point:** This patient has **chronic hepatitis C with established cirrhosis** (Child-Pugh B, MELD ~18), confirmed by: - HCV RNA positivity with high viral load - Clinical stigmata of cirrhosis (spider angiomas, palmar erythema, ascites) - Biochemical evidence (elevated INR 1.8, low albumin 2.9, thrombocytopenia) - Imaging: cirrhotic echotexture, portal hypertension (PV 13 mm) ## Management Algorithm for HCV Cirrhosis ```mermaid flowchart TD A[HCV cirrhosis diagnosed]:::outcome --> B[Screen for varices]:::action B --> C{Varices present?}:::decision C -->|Yes| D[Beta-blocker prophylaxis]:::action C -->|No| E[Repeat EGD in 2-3 years]:::action A --> F[Initiate DAA therapy]:::action F --> G[Monitor for HCV clearance]:::action G --> H[Assess for HCC surveillance]:::action A --> I[Manage portal hypertension]:::action I --> J[Diuretics + sodium restriction for ascites]:::action J --> K[Variceal bleeding prophylaxis if needed]:::action ``` ## Why Option 1 (Immediate DAA) Is Correct **High-Yield:** Modern DAA therapy (sofosbuvir-based, pangenotypic regimens) achieves sustained virologic response (SVR) in >95% of patients, **including those with cirrhosis**. The standard approach is: 1. **Baseline variceal screening** — essential before starting DAA to identify high-risk patients who need beta-blocker prophylaxis 2. **Initiate DAA** — do NOT delay; HCV eradication halts fibrosis progression and may improve synthetic function 3. **Manage ascites concurrently** — diuretics (spironolactone 100 mg daily, furosemide 40 mg daily) + strict sodium restriction (<2 g/day) 4. **Monitor for HCC** — ultrasound every 6 months; alpha-fetoprotein if cirrhosis confirmed **Clinical Pearl:** Clearing HCV in a cirrhotic patient can improve liver function and reduce decompensation risk. Even in advanced cirrhosis (Child C), DAA is indicated unless the patient is a transplant candidate with very short life expectancy. ## Ascites Management - **First-line:** Sodium restriction + diuretics (spironolactone > furosemide) - **Refractory ascites:** Therapeutic paracentesis + albumin infusion - **Transjugular intrahepatic portosystemic shunt (TIPS):** Reserved for refractory ascites or recurrent variceal bleeding despite prophylaxis ## Why Other Options Are Wrong **Option 0 (Defer ascites management):** Ascites requires concurrent management with DAA; untreated ascites increases risk of spontaneous bacterial peritonitis and hepatic encephalopathy. **Option 2 (Corticosteroids + azathioprine):** This patient has **viral hepatitis C**, not autoimmune hepatitis. Immunosuppression is contraindicated and will worsen HCV replication. **Option 3 (Transplant without DAA):** This patient is Child-Pugh B with MELD ~18 — not yet at transplant threshold (typically MELD >15 but usually >20 for listing). DAA should be attempted first; transplant is reserved for those with decompensated cirrhosis unresponsive to medical therapy or HCC.